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Summary 
To investigate the in vivo cellular tropism of human T  cell leukemia virus type II (HTLV-II), 
subpopulations of fresh peripheral blood mononuclear cells from infected individuals were isolated 
and analyzed by polymerase chain reaction for the presence of provirus. In eight of nine patients, 
HTLV-II was detected exclusively in the CD8 + T  lymphocyte population.  In the remaining 
patient,  provirus was also detected in CD4 + T  lymphocytes. Provirus was not detected in B 
lymphocytes or monocytes of any patient.  These results suggest  that  in vivo HTLV-II has  a 
preferential,  and perhaps in some cases,  an exclusive tropism  for CD8 + T  lymphocytes.  The 
findings contrast sharply with those on HTLV-I where there is a preferential tropism for CD4 + 
T  lymphocytes.  Although  HTLV-II  infection  has  not  been consistently  associated with  any 
lymphoproliferative disorders, the results suggest that if these occur, they may be different from 
those known  to be associated with  HTLV-I. 
T 
he human T cell leukemia viruses, type I (HTLV-I) and 
type II (HTLV-II) are members of a group of retroviruses 
having similar biological properties and a tropism for T lym- 
phocytes (1-3). HTLV-I is endemic in well-defined geographic 
areas,  and although the majority of infected individuals re- 
main asymptomatic, infection is associated with adult T cell 
leukemia (ATL), a malignancy of mature CD4 + T lympho- 
cytes (4-6) and a chronic neurologic disorder known as HTLV-I 
associated myelopathy/tropical spastic paraparesis (HAM/TSP) 
(7, 8). HTLV-II infection has recently been shown to be en- 
demic in certain New World native Indian populations (9-11), 
and high rates of infection have also been demonstrated in 
intravenous drug abusers (IVDAs) in North America (12-14). 
Infection however, has not yet been definitely associated with 
disease.  Whereas the virus was originally isolated from two 
patients with atypical variants of hairy cell leukemia (15, 16), 
subsequent studies have failed to reveal an association of HTLV- 
II infection with this disorder  (11, 17).  The  apparent  lack 
of pathogenidty of HTLV-II remains poorly understood. Al- 
though this may only reflect the relatively small number of 
individuals  so far identified with infection,  it may also be 
related to inherent properties of the virus and/or its cellular 
tropism.  Recent studies using the PCR have demonstrated 
that  HTLV-I has  a preferential  tropism  for CD4 + T  lym- 
phocytes in both asymptomatic patients and those with neu- 
rological disease (18). In the present study, we have used similar 
methods to determine the in vivo tropism of HTLV-II, and 
demonstrate,  in  contrast  to  HTLV-I,  that  the  virus  has  a 
preferential  tropism  for CD8 + T  lymphocytes. 
Materials and Methods 
Subjects.  Nine patients with HTLV-II infection were studied. 
HTLV-II infection  was confirmed  by virus  isolation  and  PCR 
amplification using methods previously described (14). Four of the 
patients were also infected with HIV (Table 1). All patients, except 
three (B.V.,  J.V., and W.F.) had a history of intravenous drug abuse. 
Written informed consent  was obtained before initiation  of the 
studies. 
Cell  Separation.  PBMCs  were  obtained  from  samples of 
heparinized venous blood by Ficoll-Hypaque centrifugation.  In- 
dividual cell populations were purified using a two-step selection 
procedure using washed polystyrene magnetic beads coated with 
mAbs to CD19, CD8, and CD4, respectively (Dynabeads; Dynal, 
Oslo, Norway).  An initial positive selection step was carried out 
as follows. PBMCs were incubated with anti-CD19  mAb coated 
beads (20-25  beads/target  cell), and the mixture was incubated 
in PBS containing  2%  (vol/vol) FCS and 0.02%  sodium azide 
(PBS/FCS) for 30 min at 4~  with intermittent  gentle  mixing. 
Rosetted cells were washed five times with PBS/FCS and isolated 
using a MPC-6 magnetic particle concentrator  (Dynal) according 
to the manufacturers instructions. The remaining nonrosetted cells 
were then incubated in separate steps with beads coated with mAb 
to CD4 and CD8 (five beads/target cell) under  identical condi- 
tions. To isolate monocytes, cells remaining after the positive selec- 
tion steps were incubated in RPMI-1640 medium containing  10% 
FCS for I h in polystyrene flasks at 37~  Adhered cells were washed 
and removed by cell scraping. 
Individually rosetted cell populations  were detached from the 
magnetic beads by incubation with a polyclonal antibody (Detach- 
abead; Dynal) for 45 rain at room temperature with gentle mixing. 
Detached beads were washed twice with RPMI-1640 medium con- 
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Released cells were washed three times  with PBS/FCS, and the 
populations further purified  by a negative selection procedure as 
follows.  I3,  CD4 §  and  CD8 + lymphocytes,  and  the  adherent 
monocyte populations were incubated with magnetic beads coated 
with mAbs to CD2, a mixture of CD19 and CD8, a mixture of 
CD19 and CD4, and a mixture of CD2 and CD19, respectively 
at a ratio of >50 beads/target cell.  Rosetted cells were removed 
using MPC-6 concentrator and the nonrosetted cells collected and 
used for analysis by the PCR. Flow cytometric analysis (Epics-C; 
Coulter  Cytometry,  Hialeah,  FL)  was  used  to  determine  the 
homogeneity of the cell populations. 
PCR.  Cells  were  prepared  for the  PCR using  an identical 
method described for similar studies on HTLV-I (18). After washing 
twice with PBS, cells were suspended  in distilled  water at a con- 
centration  of 107 cells/ml,  and  boiled  for  10  rain.  After brief 
centrifugation,  10-/~1 samples, representing  10  s cells, and serial ten- 
fold dilutions thereof, were analyzed.  Primers SK110 (5'CCCTA- 
CAATCCAACCAGCTCAG3') and SKlll  (5'GTGGTGAAGC- 
TGCCATCGGGTTTTY) were used to amplify a 186-bp region 
of thepol gene, and amplified products were detected by hybridiza- 
tion with an internal  oligonucleotide probe, SK188 (5'TCATG- 
AACCCCAGTGGTAA3') (19). Briefly, PCR was performed in 
a 100-#1 reaction mixture, overlaid with mineral oil,  containing 
0.2 mM of each dNTP, 50 pmol each of primer,  50 mM KC1, 2.5 
mM MgC12, and 10 mM tris-HC1 (pH 8.3),  and 2 U of Taq poly- 
merase (Perkin-Elmer  Cetus Corp., Norwalk, CT). 35 cycles were 
carried out in a thermocycler (Perkin-Etmer Cetus). Each cycle con- 
sisted of denaturation for 40 s at 94~  annealing for 55 s at 54~ 
and extension for 80 s at 72~  To ensure complete synthesis,  the 
last  cycle at  72~  was extended to 10 min.  Aliquots (15 /~1) of 
amplified  products  were  separated  by electrophoresis  on  1.5% 
agarose gels, and transferred to nitrocellulose membranes (Schleicher 
& Shuell, Keene, NH). Membranes were hybridized using condi- 
tions previously described  (14). After hybridization, membranes 
were washed twice at room temperature with 2 x  SSPE  containing 
0.1% SDS for 5 min, once at 42~  for 10 min, and then exposed 
to X-Omat AR Kodak film (Eastman Kodak Co., Rochester,  NY) 
with intensifying screens at  -70~  for 1-2 d. 
Results and Discussion 
Mononuclear cells from HTLV-II-infected patients  were 
fractionated  into  enriched  populations  of B,  CD4 +,  and 
CD8 +  T  lymphocytes,  and  monocytes using  an immuno- 
magnetic cell separation technique that was modified to en- 
sure homogeneity of the cell populations, and to reduce the 
possibility of obtaining false positive PCR results.  Analysis 
of cell  populations  by flow  cytometry demonstrated  that 
the CD4 §  and CD8 + T  lymphocytes each had purities  of 
>99.5%, and B lymphocytes, >99%. The monocyte fraction 
contained a ma.~fimum of 1.3% contamination by lymphocytes. 
PCR analysis performed on isolated cell populations from 
representative patients is shown in Fig. 1. The results of titra- 
tion experiments to determine the greatest serial dilution of 
cells  to give a positive signal in all  nine patients  is  shown 
in Table  1.  It can be seen  that  in four of the five patients 
infected with HTLV-II alone, provirus was only detected in 
the  CD8 +  T  lymphocyte population  (Fig.  1).  In  the  re- 
maining patient, (B.V.) positive signals were also detected in 
CD4 §  T  lymphocytes. However,  the number of CD4 + T 
lymphocytes infected would seem to be considerably smaller, 
at least  tenfold, compared with the CD8 + T  lymphocytes. 
In the four patients infected with both HTLV-II and HIV, 
provirus  was  only detected  in  the  CD8 +  T  lymphocytes 
(Table 1).  At present, it is unclear if the finding of provirus 
in  the  CD4 +  T  lymphocyte  population  of  one  patient 
Table  1.  Titration by PCR of HTLV-II DNA in Purified Mononuclear Cell Populations 
Detection of HTLV-II* 
CD4 §  + 
Patient/age/sex  HIV seropositivity  cells//~l*  CD19 §  CD8 §  CD4 §  Monocytes 
S.S./42/M  -  1,424/703  -  +  + +  +  - 
B.V./48/F  -  957/522  -  +  +  +  +  + 
J.V./45/M  -  1,004/517  -  +  +  - 
W.F./43/M  -  865/2,094  -  +  + +  - 
J.P./42/M  -  1,068/1,640  -  +  + +  - 
J.G./35/F  +  624/1,086  -  + +  - 
D.W./35/F  +  219/1,153  -  +  +  - 
A.C./32/M  +  277/1,094  -  +  - 
S.R./37/M  +  127/1,062  -  +  + S  _ II 
Nine patients with  HTLV-II infection, four of whom were also infected with  HIV, were studied. 
" The cell number in the greatest serial dilution to give a positive signal on PCR analysis is as follows: +, detectable in 103 cells;  + +, 104 cells; 
+ + +,  103 cells;  + + + +,  10  z cells; -,  not detectable in 10  s cells, respectively. 
* Normal values for CD4*  and CD8*  lymphocytes are 400-1,700, and 240-1,200, respectively. Patient S.R.  was persistently lymphopenic, and 
insufficient cells were available for analysis. 
S Positive signal in 5  x  103 cells. 
II Negative signal in 5  x  104 cells on repeat analysis. 
294  Cellular  Tropism of HTLV-II Figure  1.  PCR analysis of DNA from fractionated cell populations of 
five individuals with HTLV-II infection. Southern hybridization  analysis 
of amplified DNA was carried out using an internal  oligonucleotide probe 
as described in Materials and Methods.  After washing, membranes were 
exposed to X-Omat X-ray film with intensifying screens at  -70~  for 
1-2 d. The number of cell equivalents per amplification is noted above 
each lane. The autoradiographs  of W.F. and J.P. were intentionally  over- 
exposed to demonstrate  signals only in the CD8 + cells. 
represents actual infection, or whether this is due to contam- 
ination with CD8 §  T  lymphocytes. However, in view of 
the relatively high purity of the populations as determined 
by flow cytometry and the fact that  identical results were 
obtained on three separate occasions, contamination seems 
unlikely. No amplification was observed with DNA from 
B lymphocytes or monocytes of any of the nine patients, sug- 
gesting that infection of these cells does not occur in vivo. 
The observation that HTLV-II preferentially infects CD8 + 
lymphocytes in vivo contrasts with findings with HTLV-I 
where there is a preferential tropism for CD4 + T  lympho- 
cytes (18). 
At present it is difficult to accurately determine the number 
of CD8 + T  lymphocytes infected by HTLV-II, as the PCR 
assay is not quantitative, and it is unclear if infected cells have 
single or multiple copies of the provirus.  However, if it is 
assumed that  there is one provirus copy per cell,  and that 
the minimum number of cells required to produce a positive 
signal is  ten or less,  then in the individuals infected with 
HTLV-II alone, it can be estimated that at least 1%, and per- 
haps as many as 10% (patient S.S.) of the CD8 + T lympho- 
cytes are infected (Table 1). In those individuals infected with 
both HTLV-II and HIV,  the number of CD8 + T  lympho- 
cytes infected would appear to be at least tenfold less com- 
pared with those without HIV infection (Table 1). The reasons 
for this are unclear, but it might suggest that there is a selec- 
tive  loss  of  HTLV-II-infected  CD8 +  T  lymphocytes  in 
HIV-infected individuals. 
The findings that HTLV-II and HTLV-I infections are pref- 
erentially restricted to  CD8 +  and CD4 +  T  lymphocytes, 
respectively, in vivo differs from what is observed in vitro. 
Under culture conditions, both viruses have been shown to 
infect not only T and B lymphocytes (20, 21), but numerous 
nonlymphoid cell types (2, 22). These and studies with vesic- 
ular stromatitis virus-HTLV pseudotype viruses suggest that 
the HTLV-I and -II receptors are widely distributed (23). Im- 
portantly, it has also been suggested that the receptor mole- 
cule(s) for two viruses may be identical, and this has been 
mapped to the short arm of chromosome 17 (24).  Although 
the mechanisms involved in the determination of target cell 
tropism are not fully understood, our findings would sug- 
gest that factors other than the receptor molecule(s), perhaps 
both viral and/or cellular, are important in restricting HTLV-I 
and -II in vivo to the respective T  lymphocyte populations. 
The present findings may have important implications for 
studies on the role of HTLV-II in human disease.  As previ- 
ously noted, no definite disease  associations have been ob- 
served. HTLV-II was originally isolated from two patients 
with atypical variants of hairy cell leukemia (15, 16). Impor- 
tantly, subsequent evaluation of one of these patients revealed 
that the patient also  had a CD8 + lymphoproliferative dis- 
order, and the HTLV-II provirus was detected in this popula- 
tion, but not in the malignant "hairy" cells (25).  In retro- 
spect,  this was the first indication that HTLV-II has an in 
vivo tropism for CD8 §  T  lymphocytes. This observation, 
together with the results of the present study, would sug- 
gest that if HTLV-II plays a significant role in human lym- 
phoproliferative processes, these may  be quite different to what 
has been observed with HTLV-I. Prospective studies on in- 
fected individuals should determine if this is correct, and in 
addition, will show if HTLV-II infection can influence normal 
CD8 + T  lymphocyte function. 
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